Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism - Wikidata - awgldk - TriplyDB

Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism

Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism

http://www.wikidata.org/entity/Q24245782

about

Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer Warfarin initiation nomograms for venous thromboembolism Pentasaccharides for the prevention of venous thromboembolism Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer Anticoagulant therapy for deep vein thrombosis (DVT) in pregnancy Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer Subcutaneous unfractionated heparin for the initial treatment of venous thromboembolism Warfarin initiation nomograms for venous thromboembolism Low-molecular-weight heparins or heparinoids versus standard unfractionated heparin for acute ischaemic stroke Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer Home versus in-patient treatment for deep vein thrombosis Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines A novel allosteric pathway of thrombin inhibition: Exosite II mediated potent inhibition of thrombin by chemo-enzymatic, sulfated dehydropolymers of 4-hydroxycinnamic acids Diagnosis and treatment of deep-vein thrombosis A systematic review on the accumulation of prophylactic dosages of low-molecular-weight heparins (LMWHs) in patients with renal insufficiency Diagnosis and Treatment of Lower Extremity Deep Vein Thrombosis: Korean Practice Guidelines Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines Anticoagulation Therapy in Patients with Chronic Kidney Disease.Thromboembolism.Characterization of the plasma and blood anticoagulant potential of structurally and mechanistically novel oligomers of 4-hydroxycinnamic acids Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for the initial treatment of venous thromboembolism.The effect of therapeutic anticoagulation on overall survival in men receiving first-line docetaxel chemotherapy for metastatic castration-resistant prostate cancer.Anticoagulation in chronic kidney disease patients-the practical aspects.Venous thromboembolism-related mortality and morbidity in King Fahd General Hospital, Jeddah, Kingdom of Saudi Arabia.Clinical use of the low-molecular-weight heparins in cancer patients: focus on the improved patient outcomes.Some essential considerations in the design and conduct of non-inferiority trials Treatment and secondary prevention of venous thromboembolism in cancer.Comparative assessment of low-molecular-weight heparins in cancer from the perspective of patient outcomes and survival.Use of anticoagulants in elderly patients: practical recommendations Prevention and treatment of venous thromboembolism with low-molecular-weight heparins: Clinical implications of the recent European guidelines.Diagnosis and treatment of deep-vein thrombosis and approach to venous thromboembolism in obstetrics and gynecology Cerebral sinus thrombosis: a fatal neurological complication of ulcerative colitis.In too deep: understanding, detecting and managing DVT.Long-term administration of a low-molecular-weight heparin contributed to successful treatment in a patient with primary mediastinal large B-cell lymphoma and venous thromboembolism.[Anticoagulation strategies in patients with deep vein thrombosis and pulmonary artery embolisms].Outcome of Sub-Massive Pulmonary Thromboemboli in Patients Who Received Thrombolytic and or Non-Thrombolytic Therapy.Efficacy and risks of anticoagulation for cerebral venous thrombosis.Anticoagulation in the Elderly.

P2860

Q24193871-041D049B-5152-4847-BFA8-06768E4D3175 Q24201274-6701A484-6B17-4715-9A4E-56A54EE8C120 Q24234004-3828F547-5FA1-4E78-84C6-E8DF48986A09 Q24234155-4C780B18-DF3A-44B1-846C-8BA7C4D6F3E9 Q24234729-077F755C-1BF3-4751-A891-E035B5974CDA Q24235193-16329927-5989-4A55-9335-3FFEA4E787F9 Q24235236-35D08201-E2FE-4F2C-B352-147D57DF3A7D Q24236443-8669BD7C-FD1A-46F5-BF42-B25179C27936 Q24240038-654241E6-24AC-4BD5-A784-9F26AEFB2273 Q24240381-825B6D7D-EC10-4371-BD1D-DF564B7BD18D Q24241831-7FCF9477-97E6-4819-AD31-E1DCBF700266 Q24242243-36E9FC88-DBB7-4362-9C30-700E4C569543 Q24244051-6038F3FF-C716-447B-AD99-B5EA2C3898D9 Q24633053-C20E6816-CEBE-4A61-849C-D6A51B9BC454 Q24652951-50555A95-2279-4661-A480-4AE02D0C333D Q24673847-BE4658E3-A871-4DBB-A60D-67797E540D52 Q26995027-D8438C8E-1046-40BB-959B-1FB92FCAA898 Q28072833-3758BC9B-C6AC-48DD-A08D-927F4035E7CC Q33399576-A2ADACCD-6769-4F3F-98E9-8989900920B6 Q33435357-65255191-8F29-409B-A1E1-BBE34B21D748 Q33840400-11C2B213-3E76-45FA-94B1-9F8CE96EFE6C Q33899404-5F7CBC79-900E-426D-B75C-96BA31E1B837 Q34550908-2EA9C49F-F801-44BE-BCB5-F1AF42377C44 Q35095964-78ABAF28-EF2C-48C9-A52E-3E90B48B1E5E Q35232128-560185ED-8208-44AE-9EE1-DE704F47E23D Q35245237-DFC49EC6-8CD0-431E-B38E-56579F41749A Q35368813-AD7D9224-0405-482E-9414-0B0C5035A912 Q35851943-E4F5602F-F3EA-46D6-A2B2-D4A0FFCBA281 Q35865373-9132AD48-D4F2-4D2F-93DD-CE75F01CD13D Q36160668-DD069812-7890-40FD-B0A9-C85DC5B90AC2 Q37199934-FD87056D-BFB5-4042-88B2-14A137B0E989 Q37265242-8DA77FD0-09D7-468C-B1E8-9142BB3D093A Q37611378-851E3C5D-5138-43B4-B141-5C82CBE21932 Q41209195-EF2049E9-459F-4FBE-B7FE-4618E139CCB6 Q45572104-ED4BCAF8-C6F1-4BCA-8F2C-DE7D32B85D7A Q46770289-59F69B64-03AF-42AE-921B-1892D65C3896 Q49788980-A59B9D10-5009-478C-BE48-55781C4F561C Q50294512-BB54829F-AC8E-49A4-A768-8FD489FC7916 Q55255815-9AB44F9D-07E5-4E05-9EE3-255231378DAB Q55506528-57CFF65D-1166-454A-9833-568278685EF8

P2860

Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism

http://www.wikidata.org/entity/Q24245782

description

2004 nî lūn-bûn

@nan

2004 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2004 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2004年の論文

@ja

2004年論文

@yue

2004年論文

@zh-hant

2004年論文

@zh-hk

2004年論文

@zh-mo

2004年論文

@zh-tw

2004年论文

@wuu

name

Fixed dose subcutaneous low mo ...... rin for venous thromboembolism

@ast

Fixed dose subcutaneous low mo ...... rin for venous thromboembolism

@en

Fixed dose subcutaneous low mo ...... rin for venous thromboembolism

@en-gb

Fixed dose subcutaneous low mo ...... rin for venous thromboembolism

@nl

type

label

Fixed dose subcutaneous low mo ...... rin for venous thromboembolism

@ast

Fixed dose subcutaneous low mo ...... rin for venous thromboembolism

@en

Fixed dose subcutaneous low mo ...... rin for venous thromboembolism

@en-gb

Fixed dose subcutaneous low mo ...... rin for venous thromboembolism

@nl

prefLabel

Fixed dose subcutaneous low mo ...... rin for venous thromboembolism

@ast

Fixed dose subcutaneous low mo ...... rin for venous thromboembolism

@en

Fixed dose subcutaneous low mo ...... rin for venous thromboembolism

@en-gb

Fixed dose subcutaneous low mo ...... rin for venous thromboembolism

@nl

P1433

Q24245782-66503A7A-0820-40CD-8D82-8BAC5929349C

P1476

Q24245782-21F87977-F5B5-4927-9B42-641EA1885116

P2093

Q24245782-2B754C14-2485-4257-BD0A-13C8E0847D4A

Q24245782-A005B226-193A-4E1D-A4B6-DCAA349A4D56

Q24245782-C9D9755B-3810-4864-B198-A9361EE6D81D

Q24245782-FC41F6A9-55EB-4932-982B-2D948B9C30CF

P2860

Q24245782-0C674DBC-7F2F-48DF-B3B3-74966E429419

Q24245782-18B7670D-E572-4A07-821A-603F2FFE9CED

Q24245782-19AE3F2D-CF96-45CB-BE68-187ABED220A8

Q24245782-22E8F4ED-859B-45E1-9BB2-9166485C9CAC

Q24245782-2942348A-0673-456E-83CA-150C663F253A

Q24245782-3C7E2F18-5FBA-46CC-8F1E-824152369AFE

Q24245782-479F0352-3816-4061-B2FF-37E7AF860A65

Q24245782-4F034514-D622-49AC-9CB7-EB69E4C4669C

Q24245782-5528F4E1-54CC-4101-88B1-93727ABFE846

Q24245782-55D63487-894F-4FFF-B7A5-F11EFF83980C

P31

Q24245782-13730d49-2af6-41f7-95a5-781267b3c448

Q24245782-63FDA69A-9BE5-4460-A504-766396FC9001

P3181

Q24245782-A4D01204-BB30-4B08-A085-971E7E58889B

P356

Q24245782-6A3C60DB-24FA-4936-9960-FB4EFCD93A9E

P577

Q24245782-760751A0-C031-4CEB-BA8E-4FF21CA520E3

P698

Q24245782-F5932774-9429-4CB9-8F33-948CE9CE4D67

P3181

P356

14651858.CD001100.PUB2

P1433

Cochrane Database of Systematic Reviews

P1476

Fixed dose subcutaneous low mo ...... rin for venous thromboembolism

@en

P2093

AWA Lensing

http://www.w3.org/2001/XMLSchema#string

Angelique GM van den Belt

http://www.w3.org/2001/XMLSchema#string

Carlo J van Dongen

http://www.w3.org/2001/XMLSchema#string

Martin H Prins

http://www.w3.org/2001/XMLSchema#string

P2860

Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease.

Effects of a low-molecular-weight heparin on thrombus regression and recurrent thromboembolism in patients with deep-vein thrombosis.

Fixed-dose, body weight-independent subcutaneous low molecular weight heparin Certoparin compared with adjusted-dose intravenous unfractionated heparin in patients with proximal deep venous thrombosis.

Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis.

Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism.

Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis.

A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. Prévention du Risque d'Embolie Pulmonaire par Interruption Cave Study Group.

Acenocoumarol and heparin compared with acenocoumarol alone in the initial treatment of proximal-vein thrombosis.

Avoidance of large biases and large random errors in the assessment of moderate treatment effects: the need for systematic overviews.

A prospective study of the value of monitoring heparin treatment with the activated partial thromboplastin time.

P31

scholarly article

P3181

3248333

http://www.w3.org/2001/XMLSchema#string

P356

10.1002/14651858.CD001100.PUB2

http://www.w3.org/2001/XMLSchema#string

P577

2004-10-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

15495007

http://www.w3.org/2001/XMLSchema#string